INTRODUCTION: This study aimed to investigate the prevalence of red blood cell (RBC) alloimmunization in hemodialysis-dependent patients with chronic kidney disease (CKD) in Arak, Iran. There is a paucity of incidence data for the region's transfused recipients because pretransfusion antibody screening is not routine. METHODS: This study investigated the prevalence of RBC alloimmunization among patients with CKD through a cross-sectional analysis from September 2022 to February 2023. A total of 49 transfused patients (33 male and 16 female) with CKD who had received at least 1 unit of ABO- and Rh D-matched RBCs were included. Antibody screening and identification tests were performed on these patients' sera. RESULTS: The most common blood group among the patients was O Rh D positive (44.9%), followed by A Rh D positive (16.3%), B Rh D positive (14.3%), AB Rh D positive (8.2%), A Rh D negative (6.14%), B Rh D negative (6.1%), and O Rh D negative (4.1%). The mean (SD) number of RBC units transfused was 3.7 (3.3 range, 1-14) units; the median (IQR) was 3 (1-6) units. Diabetes was the most common underlying disease (n = 28 57%). None of these 49 patients was positive in our analysis for detecting antibodies against transfused RBCs. DISCUSSION: In this study, none of the patients developed RBC alloantibodies, and more than 50% had diabetes.
Yavari et al. (Tue,) studied this question.